Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 known ✓ | Q15077 | 1/20 | 0.55 |
| ▸ | RAD51 | Q06609 | 10/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 2/20 | 0.71 |
| ▸ | LTA | P01374 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | RAD1 | O60671 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415107 | 1.00 | RAD51 (1.00) | RAD51APEX1ALDH1A1KDM4EUSP2 | |
| SCHEMBL29627175 | 1.00 | RAD51 (1.00) | RAD51APEX1ALDH1A1KDM4EUSP2 | |
| SCHEMBL29351606 | 0.89 | RAD51 (0.81) | RAD51APEX1ALDH1A1KDM4EUSP2 | |
| SCHEMBL25796 | 0.89 | RAD51 (0.81) | RAD51APEX1ALDH1A1KDM4EUSP2 | |
| SCHEMBL175934 | 0.89 | RAD51 (0.81) | RAD51APEX1ALDH1A1KDM4EUSP2 | |
| SCHEMBL2333711 | 0.88 | RAD51 (0.80) | RAD51APEX1ALDH1A1KDM4EUSP2 | |
| SCHEMBL2333703 | 0.88 | RAD51 (0.80) | RAD51APEX1ALDH1A1KDM4EUSP2 | |
| SCHEMBL15823509 | 0.88 | RAD51 (0.80) | RAD51APEX1ALDH1A1KDM4EUSP2 | |
| SCHEMBL30160852 | 0.88 | RAD51 (0.80) | RAD51APEX1ALDH1A1KDM4EUSP2 | |
| SCHEMBL31389366 | 0.86 | RAD51 (0.73) | RAD51APEX1ALDH1A1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934110-B1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | UNIV GENT (BE) | 2018-08-01 | — | — | EP | claimed |
| US-9485983-B2 | Use of connexin channel inhibitors to protect grafts | UNIVERSITEIT GENT (BE) | 2016-11-08 | — | — | US | claimed |
| US-20150313208-A1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | UNIVERSITEIT GENT (BE) | 2015-11-05 | — | — | US | claimed |
| EP-2934110-A1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | Universiteit Gent (BE) | 2015-10-28 | — | — | EP | claimed |
| WO-2014095468-A1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | UNIVERSITEIT GENT (BE) | 2014-06-26 | — | — | WO | claimed |
| EP-2934110-B1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | UNIV GENT (BE) | 2018-08-01 | — | — | EP | disclosed |
| US-9485983-B2 | Use of connexin channel inhibitors to protect grafts | UNIVERSITEIT GENT (BE) | 2016-11-08 | — | — | US | disclosed |
| US-20150313208-A1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | UNIVERSITEIT GENT (BE) | 2015-11-05 | — | — | US | disclosed |
| EP-2934110-A1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | Universiteit Gent (BE) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014095468-A1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | UNIVERSITEIT GENT (BE) | 2014-06-26 | — | — | WO | disclosed |
| US-20130189280-A1 | PROTEIN DOMAINS AND USES THEREFOR | SYDNEY WEST AREA HEALTH SERVICE (SWAHS) (AU) | 2013-07-25 | — | — | US | disclosed |
| EP-2533794-A1 | PROTEIN DOMAINS AND USES THEREFOR | The University Of Sydney (AU) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011097688-A1 | PROTEIN DOMAINS AND USES THEREFOR | THE UNIVERSITY OF SYDNEY (AU) | 2011-08-18 | — | — | WO | disclosed |
| US-7419818-B2 | Organic conductor | FUJI XEROX CO., LTD (JP) | 2008-09-02 | — | — | US | disclosed |
| US-20070244309-A1 | Organic conductor | FUJI XEROX CO., LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-7238794-B2 | Organic conductor | FUJI XEROX CO., LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20030170692-A1 | Organic conductor | FUJI XEROX CO., LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1324352-A2 | Organic conductor | FUJI XEROX CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-5512667-A | Trifunctional intermediates for preparing 3'-tailed oligonucleotides | DRUG ROYALTY LP1 (CA) | 1996-04-30 | — | — | US | disclosed |
| US-5419966-A | Solid support for synthesis of 3'-tailed oligonucleotides | MICROPROBE CORPORATION (US) | 1995-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170692-A1 | Organic conductor | DNMT1, DNMT3A, POLN | P2RY6 1326/4885RAD51 932/4885APEX1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.